ARHGEF17

Across TCGA pan-cancer cohorts, ARHGEF17 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGEF17 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ARHGEF17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF17 expression acts as an unfavorable survival marker.

THYM, LIHC, and TGCT are the cancer types where ARHGEF17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LIHC	DFS	Median	II,III,IV	0.063	0.429	<.001	15	view →
TGCT	OS	Median	All	0.083	0.969	<.001	12	view →
PAAD	OS	Median	All	0.132	0.640	.018	6	view →
SARC	OS	Median	All	0.210	0.730	.022	3	view →
LUSC	OS	Median	II,III,IV	0.279	0.732	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGEF17–THYM (OS)

Open the THYM breakdown →